Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Is it worth the risk?

Annals of Surgical Oncology

Volumn 20, Issue 1, 2013, Pages 226-232

  Tsilimparis, Nikolaos ^a   Bockelmann, Christina ^a   Raue, Wieland ^a   Menenakos, Charalambos ^a   Perez, Sebastian ^b   Rau, Beate ^a   Hartmann, Jens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CARCINOMATOUS PERITONITIS; COGNITION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DYSPNEA; EMOTION; FATIGUE; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP DISORDER; SOCIAL STATUS; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APPENDICEAL NEOPLASMS; CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIARRHEA; DYSPNEA; DYSSOMNIAS; FATIGUE; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 84871785146     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2579-9     Document Type: Article

References (25)

1. Glehen O, Beaujard AC, Arvieux C, Huber O, Gilly FN. Peritoneal carcinomatosis. Surgical treatment, peritonectomy and intraperitoneal chemohyperthermia. Gastroenterol Clin Biol. 2002;26:210-215.
2. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743.
3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69-76.
4. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692-698.
5. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581.
6. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237-6242.
7. Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, et al. Modifiable and fixed factors predicting quality of life in people with colorectal cancer. Br J Cancer. 2011;104:1697-1703.
8. Piso P, Glockzin G, von Breitenbuch P, Popp FC, Dahlke MH, Schlitt HJ, et al. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol. 2009;100:317-320.
9. Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JHt, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18:3673-3679.
10. Raue W, Tsilimparis N, Langelotz C, Rau B, Schwenk W, Hartmann J. Initial results after implementation of a multimodal treatment for peritoneal malignancies. Acta Chir Belg. 2011;111:68-72.
11. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg. 2004;240:205-213.
12. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-196.
13. Hox J. Multilevel analysis. Techniques and applications. 2nd ed. New York, Routledge; 2010.
14. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345-1351.
15. McQuellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): Recommendations for care. J Surg Oncol. 2008;98:300-305.
16. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14(3):1105-1113
17. Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44:1793-1798.
18. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer quality of life questionnaire core 30. J Clin Oncol. 2010;29:89-96.
19. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53-58.
20. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (iphc) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65-73.
21. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155-162.
22. Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627-1632.
23. Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2008;51:868-874.
24. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5.
25. Zenasni F, Botella M, Elias D, Dauchy S, Boige V, Malka D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer. 2009;17:1255-1261.